Needham Upgrades Esperion to 'Strong Buy'

Analyst Mark Monane expects partnership news and pipeline progression for the cholesterol-drug therapy company

Needham upgraded Esperion Therapeutics (ESPR ) to strong buy from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.